Bowel perforation after radiotherapy in a patient receiving sorafenib.
Peters
Natascha A J B
NA
Department of Experimental Oncology, Academic Medical Center, Amsterdam, the Netherlands.
Richel
Dick J
DJ
Verhoeff
Joost J C
JJ
Stalpers
Lukas J A
LJ
D000970:Antineoplastic Agents; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced / Q000209:etiology*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib